Table 1 Characteristics of the five newly marketed drugs included in the study
From: Is new drug prescribing in primary care specialist induced?
New drug (Brand name) | Market introduction | Main indication | Reference group |
|---|---|---|---|
Salmeterol/fluticasone (Seretide/Advair) | 1999, May | Asthma/COPD* | Long acting Ī²2-agonist and ICS |
Rofecoxib (Vioxx) | 2000, Apr | Rheumatoid arthritis | NSAIDs excl. low-dose aspirin |
Esomeprazole (Nexium) | 2000, Nov | Gastro-oesophageal reflux | Proton pomp inhibitors |
Tiotropium (Spiriva) | 2002, Jun | COPD | Ipratropiumbromide containing products |
Rosuvastatin (Crestor) | 2003, Mar | Hypercholesterolemia | HMG CoA reductase inhibitors |